Northland Capital partners view on Evgen Pharma PLC: Evgen is on track to commence two phase 2 clinical trials this year. The group is building a strong clinical team in preparation for these trials. Dr Patel, who has an impressive industry track record and a breadth of relevant clinical experience, represents a key hire for Evgen. Her appointment strengthens the core team.
| Appointment of Dr Hamina J Patel as Chief Medical Officer |
| n Evgen has announced the appointment of Dr Hamina J Patel MB BCh MSc MRCPI as Chief Medical Officer.
n Dr Patel is a pharmaceutical executive with more than 15 years’ industry experience. She has led global cross functional teams in the development and commercialisation of drugs within the field of oncology. n She was previously Director of Drug Development, Oncology, at Johnson and Johnson (J&J), where she helped to build a broad and differentiated portfolio of indications for the cancer drug VELCADE®. While at J&J, she was also instrumental in the success of a new indication (the second-line treatment of mantle cell lymphoma) based on a Phase II clinical study in more than 35 countries. n She received numerous awards for her contribution to the Oncology group at J&J, including a Standard of Leadership award. n In addition to her small molecule expertise, Dr Patel has worked extensively in the development of biopharmaceuticals at Celltech and at Chugai. n Dr Patel qualified as a physician in 1990 and worked for almost ten years in hospitals around the UK before moving into the pharmaceutical industry. |
| Year end March | Revs (£m) | Adj. EBITDA (£m) | Adj. PBT (£m) | Tax (%) | Adj. EPS (p) | PER (x) | Div (p) | Net cash (£m) | Yield (%) |
| 2015A | – | (1.2) | (2.2) | – | – | – | – | (0.9) | – |
| 2016E | – | (4.1) | (3.5) | – | (4.8) | – | – | 5.4 | – |
| 2017E | – | (3.0) | (3.0) | – | (4.1) | – | – | 2.5 | – |
| 2018E | 5.0 | 1.4 | 1.4 | – | 1.7 | 16.3 | – | 4.0 | – |
| Source: Northland Capital Partners Limited. * Northland Capital Partners acts as Nomad and Broker to Evgen Pharma. |
|
|
